Journey Medical Corporation Enters into a Definitive Agreement with Dermira, Inc., a Wholly-Owned Subsidiary of Eli Lilly and Company, to Acquire QBREXZA® SCOTTSDALE, Ariz. and NEW YORK, April 01, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today...

Journey Medical Corporation Recaps 2019 Growth Potent sales and marketing model drives continued commercial success of branded dermatology products Preliminary unaudited full-year 2019 net revenue expected to be between $33 million and $36...

Journey Medical Corporation Launches Targadox™ Oral Immediate-Release Tablet for Treatment of Severe Acne Targadox™ Is Journey’s Fourth Launched Product in the Past 12 Months Availability in Major U.S. Retail and Specialty Pharmacy Chains SCOTTSDALE, Ariz., Oct. 17, 2016 (GLOBE NEWSWIRE) -- ...

Journey Medical Corporation Launches Luxamend™ Wound Cream and Ceracade™ Skin Barrier Emulsion SCOTTSDALE, Ariz., July 25, 2016 (GLOBE NEWSWIRE) -- Journey Medical Corporation, a subsidiary of Fortress Biotech, Inc. (NASDAQ:FBIO), launched the first two prescription products in its...